3D011

3D011 is a small molecule tyrosine kinase inhibitor (TKI) prodrug being developed by 3D Medicines (Sichuan) Co., Ltd. for the treatment of advanced malignant solid tumors. As a prodrug, 3D011 is designed to be metabolically converted into an active TKI moiety within the body, a strategy often utilized to optimize pharmacokinetic parameters such as oral bioavailability, systemic exposure, or safety profiles. While the specific tyrosine kinase targets (e.g., VEGFR, FGFR, or EGFR) have not been explicitly detailed in public pipeline disclosures, the agent is positioned as a targeted therapy within the company's oncology portfolio and is currently in early-stage development.